What is the 13F Pro Quality Score for ASMB?

13F Pro ranks ASSEMBLY BIOSCIENCES, INC. (ASMB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ASMB's current score at https://13fpro.ai/research/ASMB (free sign-up required for the full ranking).

Where does 13F Pro source ASMB data?

All ASSEMBLY BIOSCIENCES, INC. fundamentals and ownership data come directly from SEC EDGAR. ASSEMBLY BIOSCIENCES, INC. files with the SEC under CIK 1426800. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ASMB in?

ASSEMBLY BIOSCIENCES, INC. (ASMB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ASMB research updated on 13F Pro?

ASMB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ASSEMBLY BIOSCIENCES, INC.(ASMB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1426800 ASMB stock profile & AI dashboard →

13F Pro Quality Score

26.6/100

Rank #2,499 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

83.5/100

Profitability

7.4/100

Balance Sheet

14.1/100

Earnings Quality

30.0/100

Free Cash Flow

5.0/100

Institutional Flow

32.5/100

Revenue Scale

8.8/100

Dilution Risk

22.3/100

ASMB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ASSEMBLY BIOSCIENCES, INC. (ASMB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ASMB at 26.6/100 on a 32-signal composite quality model, placing it at rank #2,499 of 2,879 stocks — the bottom half of the AI-ranked universe. ASMB scores in the top quartile across revenue growth (83.5). Areas of concern include free cash flow (5.0) and profitability (7.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ASSEMBLY BIOSCIENCES, INC. reports quarterly revenue of $8.2M, net income of $-9.1M, free cash flow of $-22.1M. Top institutional holders of ASMB by reported 13-F value include GILEAD SCIENCES,, FARALLON CAPITAL MANAGEMENT, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. ASMB trades on the Nasdaq exchange and files with the SEC under CIK 1426800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ASMB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ASSEMBLY BIOSCIENCES, INC. directly from SEC EDGAR. ASSEMBLY BIOSCIENCES, INC.'s 13F Pro composite quality score has ranged between 9 and 31 since 2021, currently 26.6 — a stable long-term trajectory across 26 quarterly and live scoring snapshots.

✦

Fun facts about ASSEMBLY BIOSCIENCES, INC.

Quirks, history, and lore behind ASMB — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in South San Francisco, the biotech capital of the world.
2
The Numbers
A small-cap company with minimal revenue — like most clinical-stage biotechs, it runs on cash reserves and partnerships rather than product sales.
3
The History
Founded in the 2010s, it was originally focused on microbiome science before pivoting hard toward a different viral target that became its core mission.
4
The Secret
Its pipeline is laser-focused on hepatitis B virus (HBV) — a chronic infection affecting hundreds of millions globally that existing drugs suppress but rarely cure.
5
The Lore
The company's whole bet is on achieving a functional cure for HBV, combining antiviral agents to attack the virus from multiple angles simultaneously — a so-called combination therapy approach.
6
The Giveaway
Its ticker spells out what it does: assembling drug combinations to dismantle hepatitis B, one clinical trial at a time — this is Assembly Biosciences.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$8.2M

Net Income

Q1 2026

$-9.1M

Free Cash Flow

Q1 2026

$-22.1M

ROIC

Q1 2026

-5.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+153.5% YoY

$72.3MFY 2025

FY22 $0.00FY23 $7.2MFY24 $28.5MFY25 $72.3M

Net Income

+84.8% YoY

$-6.1MFY 2025

FY22 $-93.1MFY23 $-61.2MFY24 $-40.2MFY25 $-6.1M

Operating Income

+73.3% YoY

$-12.1MFY 2025

FY22 $-94.1MFY23 $-64.6MFY24 $-45.4MFY25 $-12.1M

EPS (Diluted)

+83.6% YoY

$-0.55FY 2025

FY22 $-11.54FY23 $-6.69FY24 $-3.35FY25 $-0.55

Total Assets

+116.2% YoY

$257.6MFY 2025

FY22 $101.8MFY23 $136.8MFY24 $119.2MFY25 $257.6M

Op. Cash Flow

+19.6% YoY

$-41.1MFY 2025

FY22 $-84.5MFY23 $22.7MFY24 $-51.1MFY25 $-41.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$72.3M +153.5%	$28.5M +298.2%	$7.2M	$0.00 -100.0%	$6.3M -92.1%	$79.1M
Net Income	$-6.1M +84.8%	$-40.2M +34.4%	$-61.2M +34.2%	$-93.1M +28.3%	$-129.9M -108.9%	$-62.2M
Operating Income	$-12.1M +73.3%	$-45.4M +29.7%	$-64.6M +31.3%	$-94.1M +29.1%	$-132.7M -104.8%	$-64.8M
EPS (Diluted)	$-0.55 +83.6%	$-3.35 +50.0%	$-6.69 +42.0%	$-11.54 -284.7%	$-3.00	—
Total Assets	$257.6M +116.2%	$119.2M -12.9%	$136.8M +34.4%	$101.8M -46.7%	$191.1M -32.5%	$283.3M
Operating Cash Flow	$-41.1M +19.6%	$-51.1M -324.8%	$22.7M +126.9%	$-84.5M +9.6%	$-93.4M -48.3%	$-63.0M

AI Insight: ASMB Financial Trends

ASMB achieved breakthrough profitability in Q4 2025 with $42M revenue and $22M net income, but immediately reverted to losses in Q1 2026.

• Revenue spiked to $42M in Q4 2025 from $11M in Q3 2025, then collapsed to $8M in Q1 2026.

• Net income turned positive at $22M in Q4 2025 after consistent losses, but returned to $-9M loss in Q1 2026.

• Equity jumped from $18M in Q2 2025 to $207M in Q4 2025, likely from financing activity.

• Operating cash flow improved from $-23M in Q1 2025 to $14M positive in Q4 2025.

⚠ Q4 2025 revenue spike appears non-recurring given immediate reversion to single-digit millions in Q1 2026.

⚠ Operating cash flow deteriorated back to $-22M in Q1 2026 after Q4 2025 positive performance.

AI Insight: ASMB Ratio Trends

Assembly Biosciences showed dramatic profitability swing from 52.0% net margin in Q4 2025 to -110.5% in Q1 2026.

• Operating margin swung from 46.6% in Q4 2025 to -138.4% in Q1 2026, erasing prior quarter gains.

• Net profit margin collapsed from 52.0% in Q4 2025 to -110.5% in Q1 2026.

• ROE improved dramatically from -147.9% in Q3 2024 to 42.7% in Q4 2025.

⚠ Extreme quarterly volatility in profitability metrics suggests unstable operational performance or one-time items.

⚠ Latest quarter margins returned to deeply negative levels seen throughout 2024 and early 2025.

Get alerted when ASMB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ASSEMBLY BIOSCIENCES, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ASMB

GILEAD SCIENCES, INC.
$125.0M4,505,391 sh
FARALLON CAPITAL MANAGEMENT LLC
$34.1M1,227,590 sh
RA CAPITAL MANAGEMENT, L.P.
$28.3M1,020,410 sh
Commodore Capital LP
$27.8M1,000,000 sh
JANUS HENDERSON GROUP PLC
$23.5M849,309 sh
Paradigm Biocapital Advisors LP
$18.5M665,251 sh
VANGUARD CAPITAL MANAGEMENT LLC
$13.6M490,447 sh
Parkman Healthcare Partners LLC
$11.4M411,227 sh
Point72 Asset Management, L.P.
$9.5M344,105 sh
Blackstone Inc.
$8.2M296,855 sh

Fund	Value	Shares
GILEAD SCIENCES, INC.	$125.0M	4,505,391
FARALLON CAPITAL MANAGEMENT LLC	$34.1M	1,227,590
RA CAPITAL MANAGEMENT, L.P.	$28.3M	1,020,410
Commodore Capital LP	$27.8M	1,000,000
JANUS HENDERSON GROUP PLC	$23.5M	849,309
Paradigm Biocapital Advisors LP	$18.5M	665,251
VANGUARD CAPITAL MANAGEMENT LLC	$13.6M	490,447
Parkman Healthcare Partners LLC	$11.4M	411,227
Point72 Asset Management, L.P.	$9.5M	344,105
Blackstone Inc.	$8.2M	296,855

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ASMB on your watchlist

Track score changes the day ASSEMBLY BIOSCIENCES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ASMB a good stock to buy?

13F Pro's AI-powered analysis of ASSEMBLY BIOSCIENCES, INC. (ASMB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ASMB are available on the ASMB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ASMB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ASMB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ASSEMBLY BIOSCIENCES, INC.'s investment landscape.